Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 373

Sort by

Sort Order Select

Journal Articles

Cell cycle control in Richter transformation

Christian P. Pallasch

Blood (2021) 138 (12): 1005–1007.

https://doi.org/10.1182/blood.2021011648

Published: 2021

Journal Articles

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Supriya Chakraborty, Claudio Martines, Fabiola Porro, Ilaria Fortunati, Alice Bonato, Marija Dimishkovska, Silvano Piazza, Brijesh S. Yadav, Idanna Innocenti, Rosa Fazio, Tiziana Vaisitti, Silvia Deaglio, Alberto Zamò, Aleksandar J. Dimovski, Luca Laurenti, Dimitar G. Efremov

Blood (2021) 138 (12): 1053–1066.

https://doi.org/10.1182/blood.2020008276

Published: 2021

Includes: Supplemental data

Journal Articles

Exploring the pathways to chronic lymphocytic leukemia

Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps

Blood (2021) 138 (10): 827–835.

https://doi.org/10.1182/blood.2020010029

Published: 2021

Journal Articles

A new option for Richter syndrome

Martin R. Müller

Blood (2021) 137 (24): 3318–3319.

https://doi.org/10.1182/blood.2020010621

Published: 2021

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. Miller, Brian J. Lannutti, Richard R. Furman, Katti A. Jessen, Silvia Deaglio

Blood (2021) 137 (24): 3365–3377.

https://doi.org/10.1182/blood.2020008404

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

Jenny Klintman, Niamh Appleby, Basile Stamatopoulos, Katie Ridout, Toby A. Eyre, Pauline Robbe, Laura Lopez Pascua, Samantha J. L. Knight, Helene Dreau, Maite Cabes, Niko Popitsch, Mats Ehinger, Jose I. Martín-Subero, Elías Campo, Robert Månsson, Davide Rossi, Jenny C. Taylor, Dimitrios V. Vavoulis, Anna Schuh

Blood (2021) 137 (20): 2800–2816.

https://doi.org/10.1182/blood.2020005650

Published: 2021

Includes: Supplemental data

Journal Articles

Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?

Chrysovalantou Chatzidimitriou, Theodoros P. Vassilakopoulos

Blood (2021) 137 (16): 2272.

https://doi.org/10.1182/blood.2021010664

Published: 2021

Journal Articles

Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1

Blood (2021) 137 (5): 646–660.

https://doi.org/10.1182/blood.2020005734

Published: 2021

Includes: Supplemental data

Journal Articles

Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors

Inhye E Ahn, MD, Yun-Ching Chen, PhD, Chingiz Underbayev, MD PhD, Erika M Gaglione, Clare Sun, MD, Susan Soto, Pia Nierman, Mehdi Pirooznia, MD PhD, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 850.

https://doi.org/10.1182/blood-2019-122142

Published: 2019

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 777.

https://doi.org/10.1182/blood-2019-130476

Published: 2019

Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Blood (2019) 134 (Supplement_1): 810.

https://doi.org/10.1182/blood-2019-126192

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Chingiz Underbayev, MD PhD, Inhye E Ahn, MD, Hailey Harris, Lauren T Vaughn, Mehdi Pirooznia, MD PhD, Liqiang Xi, MD, Mark Raffeld, MD, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 1287.

https://doi.org/10.1182/blood-2019-127364

Published: 2019

Journal Articles

Genome-Wide Histone Acetylation Profiling in Chronic Lymphocytic Leukemia Reveals a Distinctive Signature in Stereotyped Subset #8

Maria Tsagiopoulou, Vicente Chapaprieta, Nuria Russiñol, Fotis Psomopoulos, Nikos Papakonstantinou, Niki Stavroyianni, Achilles Anagnostopoulos, Panagoula Kollia, PhD, Elias Campo, Kostas Stamatopoulos, José I. Martin-Subero

Blood (2019) 134 (Supplement_1): 1241.

https://doi.org/10.1182/blood-2019-127817

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

NARROW

Cell cycle control in Richter transformation

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Exploring the pathways to chronic lymphocytic leukemia

A new option for Richter syndrome

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?

Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1

Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Genome-Wide Histone Acetylation Profiling in Chronic Lymphocytic Leukemia Reveals a Distinctive Signature in Stereotyped Subset #8

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only